Candel Therapeutics (CADL) announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, in the Perelman School of Medicine at the University of Pennsylvania. He is also the Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Extends Lease Agreement in Needham
- Candel Therapeutics Advances with Promising Cancer Therapies
- Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential
- Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating